These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Efficacy of Helicobacter pylori eradication in uninvestigated chronic dyspeptic staff members of a large factory: a prospective, long-term, follow-up, workplace outcome study.
    Author: Madisch A, Hotz J, Grabowski G, Guth A, Malfertheiner P, Plein K, Schneider B.
    Journal: Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):61-9. PubMed ID: 11782577.
    Abstract:
    BACKGROUND: Current European guidelines propose Helicobacter pylori eradication for the initial management of patients under 45 years with uninvestigated dyspepsia without alarm symptoms. Until now, no study has assessed this strategy in occupational medicine. AIM: To investigate the outcome of H. pylori eradication in staff members of a large factory with uninvestigated chronic dyspepsia in a prospective, open, controlled, workplace outcome study in terms of the 1 year follow-up of dyspepsia and quality of life. METHODS: In 267 subjects with uninvestigated chronic dyspepsia (229 males, mean age 42 years; range 22-62 years) H. pylori status was assessed by using the 13C-urea breath test at baseline. H. pylori-positive subjects were offered 1 week eradication therapy with omeprazole 20 mg b.i.d., clarithromycin 250 mg b.i.d., and metronidazole 400 mg b.i.d., and were retested after 2 months. Subjects with a negative 13C-urea breath test at 2 months were H. pylori-responders; subjects still H. pylori-positive at this time were H. pylori-nonresponders. H. pylori-negative subjects at baseline were included as a reference. Dyspeptic symptoms, quality of life and health care utilization were assessed by questionnaires at baseline (T0), and at 2 (T2) and 12 months (T12). RESULTS: One hundred and eleven of 267 (41.65%) subjects were H. pylori-positive at baseline. The infection was cured in 85 of 94 (90.4%) subjects. Upper abdominal pain and dyspeptic symptoms were significantly reduced and quality of life significantly increased in H. pylori responder subjects at T12 compared to baseline and to reference subjects (P < 0.01). At T12 42.3% of H. pylori responder subjects showed complete relief of epigastric pain compared to 9.2% in the reference group (P < 0.001). Furthermore, disease-related absence from work, visits to family physicians, and antacid consumption significantly decreased in H. pylori responder subjects compared with reference subjects (P < 0.05). CONCLUSION: These data suggest that an H. pylori test-and-treat strategy in occupational medicine is effective for improving uninvestigated dyspepsia and quality of life and it may reduce dyspepsia related health care costs at a level of occupational medicine.
    [Abstract] [Full Text] [Related] [New Search]